{
    "id": "347a9376-5865-d57f-e063-6394a90a4ad4",
    "indications": {
        "text": "imaavy indicated treatment generalized myasthenia gravis ( gmg ) adult pediatric patients 12 years age older anti-acetylcholine receptor ( achr ) anti-muscle-specific tyrosine kinase ( musk ) antibody positive .",
        "doid_entities": [
            {
                "text": "myasthenia gravis (DOID:437)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_437"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "full prescribing information instructions , preparation , . ( 2.1 , 2.2 , 2.3 ) evaluate need administer age-appropriate vaccines according immunization guidelines initiation imaavy . ( 2.1 ) administer via intravenous infusion . ( 2.2 ) recommended initial 30 mg/kg via intravenous infusion least 30 minutes . two weeks initial , administer maintenance 15 mg/kg via intravenous infusion least 15 minutes , continue every two weeks thereafter . ( 2.2 ) must diluted 0.9 % sodium chloride injection prior . ( 2.3 ) administer intravenous infusion via 0.2 micron in-line add-on filter . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "adverseReactions": "imaavy contraindicated patients history serious hypersensitivity reaction nipocalimab excipients imaavy . included anaphylaxis angioedema [ ( 5.2 ) ] .",
    "ingredients": [
        {
            "name": "ARGININE HYDROCHLORIDE",
            "code": "F7LTH1E20Y",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31235"
        },
        {
            "name": "HISTIDINE",
            "code": "4QD397987E",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "HISTIDINE MONOHYDROCHLORIDE MONOHYDRATE",
            "code": "X573657P6P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_27570"
        },
        {
            "name": "METHIONINE",
            "code": "AE28F7PNPL",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_16811"
        },
        {
            "name": "POLYSORBATE 80",
            "code": "6OZP39ZG8H",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53426"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "NIPOCALIMAB",
            "code": "87M90CV8NC",
            "drugbank_id": "https://go.drugbank.com/drugs/DB16257"
        }
    ],
    "organization": "Janssen Biotech, Inc.",
    "name": "IMAAVY",
    "effectiveTime": "20250506",
    "indications_original": "IMAAVY is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.",
    "contraindications_original": "See Full Prescribing Information for instructions on dosage, preparation, and administration. ( 2.1 , 2.2 , 2.3 ) Evaluate the need to administer age-appropriate vaccines according to immunization guidelines before initiation of IMAAVY. ( 2.1 ) Administer via intravenous infusion only. ( 2.2 ) The recommended initial dosage is 30 mg/kg once via intravenous infusion over at least 30 minutes. Two weeks after the initial dosage, administer a maintenance dosage of 15 mg/kg via intravenous infusion over at least 15 minutes, and continue every two weeks thereafter. ( 2.2 ) Must be diluted with 0.9% sodium chloride injection prior to administration. ( 2.3 ) Administer as an intravenous infusion via a 0.2 micron in-line or add-on filter. ( 2.3 )",
    "adverseReactions_original": "IMAAVY is contraindicated in patients with a history of serious hypersensitivity reaction to nipocalimab or any of the excipients in IMAAVY. Reactions have included anaphylaxis and angioedema\n \n  [see\n  \n   Warnings and Precautions (5.2)]\n \n  .",
    "drug": [
        {
            "name": "IMAAVY",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31235"
        }
    ]
}